News
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical trial participants who took tirzepatide,
Tirzepatide is more effective than semaglutide for weight loss, according to a new study on GLP-1 medications ; The study was ...
A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...
While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...
A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...
The best metric is not weight, but a particularly toxic kind of fat.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback